CFTR Modulators in Pregnancy and Postpartum

Real-world Efficacy and Safety of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy in Adult Patients With Cystic Fibrosis (CF)

NCT05526027 ·Status: UNKNOWN ·Phase: NA

Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

NCT04509050 ·Status: RECRUITING

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

NCT06296394 ·Status: RECRUITING

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

NCT00909727 ·Status: COMPLETED ·Phase: PHASE3

Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del

NCT02653027 ·Status: WITHDRAWN ·Phase: NA

Response to CFTR Modulators in CF Patients Under 18 Years

NCT04301856 ·Status: RECRUITING

Ensuring Access to Optimal Therapy in CF: The ENACT Study

NCT07148739 ·Status: RECRUITING ·Phase: PHASE4

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

NCT00457821 ·Status: COMPLETED ·Phase: PHASE2

Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects

NCT02603666 ·Status: COMPLETED ·Phase: NA

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

NCT02725567 ·Status: COMPLETED ·Phase: PHASE3

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation

NCT00909532 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis

NCT05530278 ·Status: COMPLETED ·Phase: PHASE1

Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

NCT03450720 ·Status: COMPLETED ·Phase: PHASE1

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

NCT02707562 ·Status: COMPLETED ·Phase: PHASE2

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

NCT00953706 ·Status: TERMINATED ·Phase: PHASE2

Inhaled Therapy Adherence and Outcomes to Kaftrio in Cystic Fibrosis

NCT05519020 ·Status: COMPLETED

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

NCT02070744 ·Status: COMPLETED ·Phase: PHASE2

Single Dose of pGM169/GL67A in CF Patients

NCT00789867 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

NCT01531673 ·Status: COMPLETED ·Phase: PHASE2

Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients

NCT00376428 ·Status: TERMINATED ·Phase: PHASE2

A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

NCT02508207 ·Status: COMPLETED ·Phase: PHASE2

Treatment With Elexacaftor/Tezacaftor/Ivacaftor, in Patients With Cystic Fibrosis and Caloric Intake

NCT06072365 ·Status: COMPLETED

Impact of Triple Combination CFTR Therapy on Sinus Disease.

NCT04056702 ·Status: UNKNOWN

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

NCT01614470 ·Status: COMPLETED ·Phase: PHASE3

A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients

NCT02722057 ·Status: COMPLETED